Biodelivery sciences international, inc. announces significant additional insurance coverage for both belbuca® and symproic®

Biodelivery sciences international, inc. announced that a major pbm will begin providing improved patient access to belbuca® (buprenorphine buccal film), ciii, and symproic® (naldemedine) tablets 0.2 mg beginning october 1, 2019, with full plan adoption by january 1, 2020. this will enable approximately 14 million covered lives within both commercial and health exchange plans to access belbuca as either the preferred or preferred exclusive buprenorphine product within their respective plans and symproic as the preferred exclusive product within its class. the addition of this large national pbm brings the total number of commercial lives with preferred access to belbuca to more than 104 million (out of more than 160 million with coverage) and more than 76 million overall covered lives for symproic.
BDSI Ratings Summary
BDSI Quant Ranking